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An increasing interest in treating individuals at risk of rheumatoid
arthritis (RA) to prevent the development of this chronic condition
has focussed attention on the identiﬁcation of risk factors of this
disease. Most patients who develop RA progress through a pre-
ceding symptomatic phase that may take the form of arthralgia,
palindromic rheumatism or unclassiﬁed arthritis before a disease
currently classiﬁable as RA is established. An understanding of
symptoms that identify individuals as being at risk of RA is a
critical issue. Constellations of relevant symptoms could (1) form
the basis of public health campaigns to encourage rapid consul-
tation, (2) inform primary health care providers regarding which
patients to perform additional tests in or whom to refer to a
rheumatologist and (3) be included in algorithms to predict RA
development. In this review, we present qualitative and quanti-
tative data summarising current understanding of the symptoms
experienced by individuals at risk of RA.
© 2017 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Patients may transition between clinical states before rheumatoid arthritis (RA) manifests. Ge-
netic and environmental risk factors predate the development of autoimmunity; in seropositive
patients, the development of autoantibodies, such as rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPA), can be present for up to a decade before symptoms emerge [1e3].ier Ltd. This is an open access article under the CC BY-NC-ND license (http://
G.S. Jutley et al. / Best Practice & Research Clinical Rheumatology 31 (2017) 59e7060Individuals at risk of RA may progress to develop symptoms but without clinical arthritis (a phase
that has also been termed ‘clinically suspect arthralgia’ (CSA) when a rheumatologist has a high index
of suspicion for the development of future clinical joint swelling and subsequently RA) [4], palin-
dromic rheumatism or persistent unclassiﬁed arthritis (UA) before eventually developing RA [5].
Whether patients with inﬂammatory arthritis are categorised as having UA or RA depends in part on
which set of RA classiﬁcation criteria are applied; for example, the 2010 ACR/EULAR criteria tend to
classify more patients as having RA than the 1987 ACR criteria [6e8]. Consequently, the symptoms
associated with inﬂammatory arthritis that does not meet the 2010 ACR/EULAR RA (UA 2010) could
be subtly different from those associated with inﬂammatory arthritis that does not meet the 1987
ACR criteria for RA (UA 1987).
Evidence suggests that the earliest clinically apparent stages of RA offer an important therapeutic
window, where timely treatment can signiﬁcantly alter disease progression and outcome [9e11]. Many
have extrapolated to propose that treating patients who are symptomatic and at high risk of future RA
development may lead to enhanced clinical outcomes. Methotrexate has been shown to delay the
onset of 1987 classiﬁable RA and radiographic progression of disease in 1987 classiﬁable UA patients
[12]. Currently the effects of B [13,14] and T [15] cell-modulating therapy on individuals at risk of RA are
being investigated.
Approaches to identify individuals at risk of RA have taken a number of different forms including [1]
targeting members of the general population or ﬁrst-degree relatives of patients with RA and assessing
them for RA-related autoantibodies and symptoms and [2] targeting patients who present either to
primary or secondary care with musculoskeletal symptoms and quantifying risk on the basis of vari-
ables including symptoms and the results of laboratory and imaging tests. Clearly, the pre-test prob-
ability of RA development and thus the predictive value of speciﬁc risk factors in these scenarios are
different. Nevertheless, an understanding of which symptoms are associated with RA development is
relevant in all these contexts. As such there is need for more insight into symptoms in those at risk of
RA [16e18]. Qualitative approaches provide a valuable opportunity to understand the nature of
symptoms in individuals at risk of RA but not without limitations. Reporting of symptoms retrospec-
tively by RA patients are subject to recall bias. Furthermore, contemporaneous symptom reporting can
also be problematic as not all individuals will develop RA. Ideally, a longitudinal mixed methods
approach would be required to assess differences in symptom complexes between those who even-
tually develop RA and those who do not. To date, a number of quantitative studies have been under-
taken to explore the symptoms in patients at risk of RA and relate these to future RA development. An
important limitation of these studies is that the domains across which symptom data are collected are
based upon physician's pre-conceptions of what symptoms are likely to be present in at-risk in-
dividuals rather than on data from qualitative studies that have captured the symptomatology of at-
risk individuals. Such pre-conceptions are largely informed by an understanding of the symptoms
associated with established RA, and clinical experience of seeing and following up ‘at-risk’ individuals,
especially those with UA.
The aim of this review is to present literature that has explored symptoms in patients prior to the
fulﬁlment of classiﬁcation criteria for RA, with a focus on patients with musculoskeletal symptoms
prior to the onset of clinically apparent joint swelling.Data from quantitative research
Quantitativework has been undertaken to explore the symptoms of individuals at risk of RA. Survey
questions are largely based on symptoms characteristic of established RA and are therefore assumed to
be present in at-risk individuals too [19]. Tables 1 and 2 summarise quantitative work undertaken in
patients with musculoskeletal symptoms prior to the onset of clinically apparent joint swelling and
patients with UA, respectively.
Common clinical manifestations in symptomatic patients prior to the development of joint swelling
include symmetrical pain affecting the upper and lower extremities [20e22], in particular the small
joints of the hands [21,22]. A greater proportion of those with early morning stiffness that lasted more
than 60 min went on to develop inﬂammatory arthritis at follow-up [22]. A cross sectional analysis
Table 1
Studies in patients at risk of RA with musculoskeletal symptoms but without clinically apparent joint swelling: quantitative data relating to demographic, clinical and laboratory variables.
van de Stadt et al. (n ¼ 374) [21] van Steenbergen et al. (n ¼ 150) [22] Rakieh et al. (n ¼ 100) [20]
Inclusion criteria positive ACPA and/or Immunoglobulin-M-RF status and
(a history of) arthralgia
Clinically Suspect Arthralgia of the small joints for <1 year
that was, according to a rheumatologist, suspected to
progress to RA over time
Positive ACPA and new non-speciﬁc
musculoskeletal symptoms
Demographical
characteristics
Progression to
RA (n ¼ 131)
No progression to
RA (n ¼ 243)
Hazard Ratio (HR)
(95% Conﬁdence
Interval [CI])
Progression to
inﬂammatory
arthritis (n ¼ 30)
No progression to
inﬂammatory
arthritis (n ¼ 119)
HR Frequency [ n/N (%)
progressed to
Inﬂammatory
arthritis]
HR (95% CI)
Age in years, mean
(standard
deviation [SD])
47 (11) 49 (12) 0.99 (0.98e1.00) 43.9 (12.7) 43.1 (12.8) 1.004 (0.98e1.03)
Female, (number
[n]) (%)
97 (74) 188 (77) 0.95 (0.64e1.42) 22 (73.3) 87 (73.1) 1.02 (0.45e2.29)
Family history
positive for
rheumatoid
arthritis (RA),
n (%)
38 (29) 48 (20) 1.26 (0.86e1.85) 12 (40) 38 (31.9) 1.37 (0.66e2.85) 11/25 (44) 1.25 (0.64e2.46)
BMI in kg/m2, mean
(SD)
26.7 (6.1) 26.5 (5.0) 1.01 (0.94e1.08)
Present smoker,
n (%)
9 (30) 29 (24.4) 1.28 (0.59e2.79)
Symptoms characteristics
Symptom duration
in weeks, med
(interquartile
range [IQR])
17 (8e30) 18 (10e31) 0.99 (0.98e1.01)
Joint symptoms of
recent onset
(<1 year)
48 (37) 72 (30) 1.47 (1.02e2.11) 15/31 (48) 1.05 (0.57e1.92)
Gradual symptom
onset (>1 week)
22 (73.3) 95 (80.5) 0.68 (0.30e1.53)
Morning stiffness
60 min n (%)
31 (24) 37 (15) 1.94 (1.29e2.91) 15 (50) 38 (33.6) 1.89 (0.92e3.87) 13/22 (59.1) 1.92 (1.02e3.63)
Intermittent
symptoms
68 (52) 64 (26) 2.2 (1.56e3.11) 12/20 (60) 1.27 (0.66e2.44)
Visual analogue
score (VAS) pain
50, n (%)
59 (45) 69 (28) 1.87 (1.32e2.64) 11/25 (44) 1.26 (0.64e2.5)
Small joints n (%) 96 (73) 164 (68) 1.07 (0.72e1.60) 19 (63.3) 107 (90.7) Not recorded
(continued on next page)
G
.S.Jutley
et
al./
Best
Practice
&
Research
ClinicalRheum
atology
31
(2017)
59
e
70
61
Table 1 (continued )
van de Stadt et al. (n ¼ 374) [21] van Steenbergen et al. (n ¼ 150) [22] Rakieh et al. (n ¼ 100) [20]
Small and large
joints n (%)
9 (30) 6 (5.1) 5.28 (2.38e11.73)
Large joints n (%) 2 (6.7) 5 (4.2) 1.89 (0.44e8.14)
Upper extremities n
(%)
20 (66.7) 88 (73.9) Nil
Upper & lower
extremities n (%)
80 (60) 109 (45) 1.64 (1.15e2.34) 7 (23.3) 21 (17.6) 1.47 (0.62e3.47) 22/37 (60) 1.38 (0.79e2.41)
Lower extremities
n (%)
3 (10) 10 (8.4) 1.36 (0.40e4.58)
Symmetry n (%) 102 (78) 174 (72) 1.31 (0.87e1.98) 19 (63.3) 91 (77.1) 0.59 (0.28e1.23)
Laboratory characteristics
C-Reactive protein
(CRP) level in mg/
L, med (IQR)
1.5 (0e14.5) 0 (0e4) 1.06 (1.03e1.09)
hsCRP  2 mg/dL 24/43 (56) 1.27 (0.66e2.42)
CRP level >5 mg/L,
n (%)
14 (11) 22 (9) 1.29 (0.73e2.26) 10 (33.3) 21 (17.6)
Rheumatoid factor
(RF)-positive
(>3.5 IU/mL), n
(%)
18 (60) 15 (12.6) 6.94 (3.34e14.43) 9/15 (60) 1.69 (0.77e3.69)
Anti-citrullinated
protein
antibodies
(ACPA) positive
(>7 U/mL), n (%)
16 (53.3) 8 (6.7) 10.07 (4.87e20.82) 50/100 (50) 1.43 (0.64e3.19)
RF and ACPA
positive
67 (51) 44 (18) 8.87 (4.79e16.41)
G
.S.Jutley
et
al./
Best
Practice
&
Research
ClinicalRheum
atology
31
(2017)
59
e
70
62
Table 2
Studies in patients with undifferentiated arthritis: quantitative data relating to demographic, clinical and laboratory variables.
Duer-Jensen et al. (n ¼ 116) [25] van der Helm-van Mil et al. (n ¼ 570) [24]
Inclusion Criteria >2 tender joints and/or >2 swollen joints among
the metacarpophalangeal, proximal
interphalangeal, wrist, or metatarsophalangeal
(MTP) joints for >6 weeks but <24 months,
without a speciﬁc rheumatology diagnosis in
particular not fulﬁlling 1987 classiﬁcation
American College of Rheumatology (ACR) criteria
for RA.
Newly presenting inﬂammatory arthritis and not
fulﬁlling 1987 ACR classiﬁcation criteria for RA or
criteria for another classiﬁable inﬂammatory
arthritis
Demographical
characteristics
RA progression
(n ¼ 27)
No RA progression
(n ¼ 89)
P-value RA progression
(n ¼ 177)
No RA progression
(n ¼ 393)
P-value
Age in years, mean
(standard
deviation [SD])
50 (21e80) 47 (19e82) 0.74 56.3 (15.3) 48.6 (17.0) <0.001
Female, number (n)
(%)
22 (81.5) 68 (76.4) 0.79 121 (68) 208 (53) 0.001
Family history
positive for RA, n
(%)
54 (31) 81 (21) 0.01
Present smoker, n
(%)
84 (47) 187 (48) 1.0
Symptoms characteristics
Symptom duration,
median (range)
months (SD)
4 (2e18) 7 (1.5e24) 0.17
Symptom duration
>6 months
61 (36) 107 (28) <0.001
Gradual symptom
onset (>1 week)
86 (49) 141 (36)
Morning stiffness
60 min, n (%)
14 (51.9) 19 (21.8) 0.01
Morning stiffness
visual analogue
score (VAS) (0
e100) (SD)
53.3 (30.1) 35.5 (30.0) <0.001
Rheumatoid
nodules, n (%)
0 (0) 0 (0) 1.0
Pain VAS 49 (12e77) 33.5 (0e98) 0.001
Small joints, n (%) 95 (54) 171 (44)
Large joints, n (%) 32 (18) 165 (42)
Small and large
joints, n (%)
50 (28) 57 (15) <0.001
Upper extremities,
n (%)
71 (40) 177 (45)
Lower extremities,
n (%)
22 (12) 139 (35)
Upper and lower
extremities, n (%)
84 (47) 77 (20) <0.001
Symmetry, n (%) 5 (18.5) 11 (12.4) 0.52 118 (67) 147 (37) <0.001
Laboratory characteristics
C-reactive protein
(CRP) level in mg/
L, med
(interquartile
range [IQR])
14 (7e13) 8 (3e21) <0.001
Erythrocyte
sedimentation
rate, median
(IQR) mm/h
32 (19e53) 17 (8e38) <0.001
Elevated CRP
(5 mg/L), no. (%)
19 (70.4) 30 (34.1) <0.01
(continued on next page)
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Table 2 (continued )
Duer-Jensen et al. (n ¼ 116) [25] van der Helm-van Mil et al. (n ¼ 570) [24]
Rheumatoid factor
(RF) positive
(>3.5 IU/mL), n
(%)
16 (59.3) 18 (20.5) <0.01
ACPA positive (>7
U/mL), n (%)
9 (33.3) 8 (9.0) <0.01
G.S. Jutley et al. / Best Practice & Research Clinical Rheumatology 31 (2017) 59e7064conducted on a Dutch cohort suggested that increased early morning stiffness correlates with RA
development in symptomatic ‘at-risk’ patients [23].
Similar to patients with musculoskeletal symptoms prior to the onset of clinically apparent joint
swelling, patients with UA (not fulﬁlling 1987 ACR criteria for RA) who eventually develop RA report
symmetrical symptoms affecting the upper and lower extremities with prolonged morning stiffness
[24,25].
Predictive algorithms including demographic, clinical and laboratory variables have been developed
for predicting the development of RA in patients with autoantibody-positive arthralgia [21] and UA (as
deﬁned by 1987 ACR criteria for RA) [24,26]. Symptoms are included in the clinical components of each
model for respective at risk populations. In patients with seropositive arthralgia, symptoms of recent
onset, which were intermittent, affected the upper and lower extremities, and were associated with
more than 1 h of early morning stiffness, identiﬁed those more likely to progress to RA [21]. Similarly,
symmetrical symptoms affecting the upper and lower extremities with severe morning stiffness
increased the likelihood of UA patients developing RA [24]. The importance of the location of symp-
toms has also been highlighted in a prospective cohort study of patients identiﬁed in primary carewith
non-speciﬁc musculoskeletal symptoms without clinical synovitis; patients with pain in the wrists,
hands, feet and shoulders were more likely to be ACPA positive, although the association between
symptoms and progression to RA was not analysed due to limitations in sample size [27].
There is a chance that some critical symptoms (that are either common and or discriminatory) in
this early phase were overlooked in these quantitative studies as they were not assessed. Therefore,
qualitative studies are important to identify the full range of symptoms associated with musculo-
skeletal symptoms prior to the onset of clinically apparent joint swelling, which can subsequently be
explored in quantitative research to assess relationships with RA development and utility in predictive
algorithms.
Data from qualitative research
Qualitative approaches provide an opportunity to explore the full range of symptoms and symptom
complexes experienced by individuals during the ‘at-risk’ stages of RA. Different qualitative methods
can be used to capture these data; these could include qualitative interviews and focus groups.
Qualitative data regarding the experience and impact of symptoms have been collected from 15
ACPA-positive patients with arthralgia and from 11 newly diagnosed RA patients [28]. Focus group
discussions and semi-structured interviews were guided by an interview schedule developed from a
review of the literature and in consultation with patient research partners. An interactive feedback
procedure was used between ACPA-positive arthralgia patients and patients newly diagnosed with RA.
This process allowed each group of participants to reﬂect on the experiences of the other group. The
patients' symptoms were grouped into six major themes as described below.
Pain in and around the joints was a key symptom. Many symptomatic ACPA-positive patients
appeared to experience less intense pain than the early RA patients. Most early RA patients gave an
account in which the experience of pain gradually increased in intensity before the diagnosis of RA.
Some symptomatic ACPA-positive patients likened the pain to muscle soreness experienced after
strenuous exercise. The pain in symptomatic ACPA-positive patients affected sleep and was recurrent
in nature, with many patients describing it as ‘bothersome’ and ‘annoying’. Additionally, symptomatic
G.S. Jutley et al. / Best Practice & Research Clinical Rheumatology 31 (2017) 59e70 65ACPA-positive patients stated that the onset of pain often followed exertion or some form of mild
trauma and was sometimes preceded by tingling sensations around the joints [28].
Joint redness, warmth and swelling represented another important symptom theme. Some
symptomatic ACPA-positive patients experienced transient episodes of joint swelling, with burning
sensations, warmth and redness of the skin around their joints during episodes of swelling. Patients
newly diagnosed with RA also recalled burning sensations around the joints at symptom onset; with
the beneﬁts of hindsight, they reported a discrepancy between the pain they experienced and the
intensity of their joint swelling at the onset of their symptoms. Some described considerable initial
pain in the absence of swelling and that when the swelling eventually developed, at least initially, it
was frequently transient and migratory [28].
Joint stiffness was another commonly reported symptom. Some symptomatic ACPA-positive pa-
tients described classical morning stiffness, whilst others described stiffness that was worse in the
evenings. In some cases, the stiffness was described as ‘painful’, restricting the range of movement and
associated with numbness. Symptomatic ACPA-positive patients noted that stiffness duration
increased as their disease progressed [28].
The fourth theme represented weakness and loss of motor control. Symptomatic ACPA-positive
patients described transient episodes of loss of muscle function that had resulted in falls and objects
being dropped; these episodes could occur abruptly and unexpectedly. Other patients described
persistent weakness. Some symptomatic ACPA-positive patients reported having to use specialist
equipment to aid in activities associated with daily living [28].
Fatigue, sleeping difﬁculties and depressive symptoms were commonly reported. Extreme fa-
tigue resulting in symptomatic ACPA-positive patients falling asleep or feeling unable to get up from
the ﬂoor was reported. Patients described pain as an obstacle to sleep, and some patients associated
fatigue with the sleeping difﬁculties they experienced. Some described ﬂuctuations in fatigue with
onset heralding the onset of other symptoms [28].
The ﬁnal theme is related to the pattern of symptom experience and onset. Many symptomatic
ACPA-positive patients described migratory and palindromic episodes with symptoms lasting for days
before dissipating. In contrast, as symptoms progressed towards RA, symptomatic episodes would last
longer before eventually persisting without episodes of resolution in between [28].
This qualitative study thus highlighted a constellation of symptoms described by patients, with
symptomatic ACPA-positive individuals at risk of RA that have previously not been captured in
quantitative work. These included numbness; restricted movements; loss of strength; sudden loss of
function (dropping objects); muscle fatigue; muscle cramps; abnormal skin sensations; weight loss;
and burning sensation, warmth and redness around the joint.
The symptoms experienced by symptomatic ACPA-positive patients, as outlined above, are
burdensome, with considerable physical and psychological impact [29]. Physical impact resulted, in
part, from difﬁculties with hand function and mobility. Tasks such as dressing, washing, eating and
household chores were compromised. A common sentiment of apprehension and uncertainty was
present as patients did not know if their disease would progress to RA. Such ‘at-risk’ patients also
described low mood and in some cases a considerable psychological impact of their symptoms (‘It
started in mywrist, moved to my elbow and hands. A terrible pain, you can't hold anything. It lasted for
two days. I didn't sleep for nights. I thought if this is my future, then I want to get out’ [29]). Patients had
speciﬁc fears of developing RA and subsequent disease progression leading to life-limiting disability.
Patients also experienced, shame, despair and frustration [29]. Interestingly, many of the psychological
symptoms experienced were as a result of fear of the unknown as opposed to a consequence of the
physical impact of the symptoms experienced at the time. The resulting disability from physical and
psychological symptoms of individuals at risk of RA can be profound. A recent study of 255 patients
with CSA for less than 1 year showed functional imitations as measured by HAQ comparable to those
with early arthritis [30].
A separate focus group conducted with four female CSA patients (three seronegative and one
seropositive) explored their perceptions of their condition [31]. Patients described difﬁculty in per-
forming a range of activities such as putting on shoes, going hiking, shaking hands and avoiding social
situations entirely [31]. In addition, patients discussed the effect of CSA on personal control, engaging
in health-promoting behaviours such as dietary change and practicing yoga [31]. CSA patients
G.S. Jutley et al. / Best Practice & Research Clinical Rheumatology 31 (2017) 59e7066expressed concern and fear of pain reoccurrence during pain-free periods. There was also fear of
disease progression with accompanying symptom ampliﬁcation [31].
Patients with palindromic rheumatism [32] represent a distinct subset of at-risk individuals, and
some data are available regarding the symptoms experienced by patients with this diagnosis. A
quantitative study of 39 patients diagnosed with palindromic rheumatism revealed periodic acute
onset of joint swelling [32]. Joint swelling typically lasted hours to days (though could last up to two
weeks), with asymptomatic periods between episodes [32]. A spectrum of pain was reported, from
mild to debilitating. Less common symptoms included fever, which accompanied episodes of arthritis,
skin nodules and a change in skin colour over the affected area [32]. A survey conducted on 60
palindromic rheumatism patients revealed similar ﬁndings, highlighting that ﬂares tend to be mon-
oarticular [33]. Data from a qualitative study in 17 patients with palindromic rheumatism showed that
most patients experienced transient symptoms of progressive intensity [34]. Palindromic ﬂares were
characterised by intense pain, followed by swelling of a joint. In addition, patients reported soreness,
burning sensations, tenderness, stiffness, warmth and colour change at or around the joint. Less
frequently transient nodules, painful skin lesions, fatigue and depression were also described.
Symptoms typically evolved over time, increasing in frequency and severity in the majority of patients
[34]. The unpredictable nature of the attacks caused psychological and emotional distress. Some
patients postulated ﬂares to be triggered by lifestyle factors such sleep deprivation, alcohol, diet and
stress [34].
Data from qualitative studies in individuals at risk of RA have been used to inform the development
of a questionnaire, which aims to capture the prevalence of these symptoms quantitatively; work on
this is currently ongoing [35].
Aetiology of symptoms in patients with clinically suspect arthralgia
Symptoms in individuals at risk of RA are often considerable. Although it is postulated that many of
these symptoms can be attributable to synovitis in those with palindromic arthritis or UA, this has not
been shown. The explanation for articular and extra-articular symptoms in patients with CSA without
clinically identiﬁable joint swelling is less obvious. One potential explanation is clearly the presence of
subclinical synovitis or tenosynovitis, and several studies have investigated this using different im-
aging modalities.
MRI of the symptomatic joints of the hands and feet in 21 ACPA-positive patients without clinical
arthritis revealed evidence of bone marrow oedema and synovitis at symptomatic wrist, MCP, PIP and
MTP joints in some but not all patients [36]. Comparable ﬁndings have been reported in seronegative
CSA patients [37]. A similar study from a different group looking at ACPA-positive arthralgia patients
showed that 26 of 28 patients had a RAMRIS synovitis score of at least one in at least one hand or wrist
joint, with 10 patients having a synovitis score of at least two in at least one joint [38]. One important
consideration in the context of such imaging studies is the frequency of subclinical synovitis in
apparently healthy joints. Of the four asymptomatic healthy controls also included in this study, all had
an MRI synovitis score of at least one in at least one joint [38]. Whilst subclinical synovitis may be
present in many patients with CSA, some patients experienced joint-related symptoms in the absence
of such synovitis. Furthermore, such synovitis can be present in healthy individuals without joint
symptoms. The relationship between symptoms and subclinical synovitis is thus not straightforward.
A prospective longitudinal study of 150 CSA patients (both seropositive and seronegative) assessed
the ability of MRI-detected abnormalities to predict the development of clinically apparent inﬂam-
matory arthritis [22]. MRI-detected synovitis, bone marrow oedema and tenosynovitis were all asso-
ciated with future arthritis development [22]. Importantly, arthritis development was unusual in the
absence of subclinical synovitis [22].
Ultrasound has also been used as an imaging modality to assess the presence of synovitis in in-
dividuals at risk of RA. Whilst ultrasound evidence of synovitis (both grey-scale and power Doppler) is
present in ACPA-positive patients without clinical arthritis [39] and its presence is associated with
future arthritis development [39,40], the majority of painful or tender joints in patients with auto-
antibody positivity and musculoskeletal symptoms did not have ultrasound evidence of synovitis (as
judged by the presence of effusion, synovitis or power Doppler) [40].
G.S. Jutley et al. / Best Practice & Research Clinical Rheumatology 31 (2017) 59e70 67In addition to ultrasound and MRI, macrophage positron emission tomography has also been
used to image ACPA-positive arthralgia patients [41]. Of 29 ACPA-positive arthralgia patients, 4 had
a positive PET-CT scan of at least one of the hand or wrist joint. All 4 patients developed RA at
follow-up [41].
Thus in a proportion of patients with CSA, including patients with CSAwho are known to eventually
develop RA, imaging fails to reveal subclinical synovitis. Furthermore, a study of the synovium from
autoantibody-positive patients who either had arthralgia or a ﬁrst-degree relative with RA showed no
overt histological synovitis from knee joint synovial biopsies despite the fact that in almost half the
patients, the knee joint was symptomatic [42]. Consequently, histological synovitis also does not fully
explain the prevalence of joint symptoms in patients with musculoskeletal symptoms and autoanti-
body positivity at risk of RA. Interestingly, recent data suggests that ACPA itself may play a role in the
development of joint-related symptoms in the absence of discernible joint inﬂammation. Murinised
monoclonal ACPA injected into mice gave rise to pain behaviour, with IL-8 pathways implicated,
without any visual or histological evidence of joint inﬂammation [43].
Whilst subclinical synovitis and tenosynovitis may explain some of the joint related symptoms in
patients at risk of RA prior to the onset of joint swelling and autoantibodies may play a role in the pain
experience in some symptomatic autoantibody positive patients, the explanation for joint related
symptoms in all patients with arthralgia who eventually develop RA remains unclear as are the causes
of some of the extra-articular symptoms in this patient group.
A EULAR deﬁnition of clinically suspect arthralgia
In an attempt to provide clarity and consistency regarding nomenclature, a EULAR-supported
initiative has aimed to deﬁne CSA with a particular emphasis on symptoms that predict progression
to RA [4]. A taskforce of rheumatologists, health professionals, patients and a methodologist
approached this using a three-step process. In the ﬁrst phase, signs and symptoms associated with CSA
were agreed upon and weighted according to relevance to distinguish arthralgia that precedes RA from
other types of arthralgia. In the second phase, experts reviewed 50 cases of patients previously pre-
senting with arthralgia without clinically detectable arthritis. Of these, 26 patients had been classiﬁed
by the treating rheumatologist as having CSA. The experts were blinded to this classiﬁcation and were
presented with clinical data relating to the parameters selected in phase one. The experts were then
asked to classify the patient as CSA or non-CSA and to provide a level of conﬁdence in their classiﬁ-
cation using a numerical rating scale. In phase three, data were collected from new patients with and
without CSA (according to the managing rheumatologist) to validate the parameters selected from
phase two, resulting in characteristics, including symptoms (see Box 1), which describe CSA at risk of
RA development [4].Box 1
EULAR symptoms describing CSA at risk of RA development.
History taking:
Joint symptoms of recent onset (duration <1 year)
Symptoms located in MCP joints
Duration of morning stiffness 60 min
Most severe symptoms present in the early morning
First-degree relative with RA
Physical Examination:
Difficulty making a fist
Positive squeeze test of MCP joints
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This review has highlighted a wide range of symptoms experienced by individuals at risk of RA.
These include not only the articular symptoms widely recognised to be associated with established RA
(e.g. pain, swelling, stiffness) but other symptoms including joint redness, weakness and loss of motor
control, sleeping difﬁculties, fatigue and depressive symptoms. These symptoms are not only impor-
tant for clinicians in the context of prognostication but have far reaching physical and psychological
consequences for the patient, which should be addressed during their clinical management.
A better understanding of symptoms in individuals at risk of RA will help inform public health
campaigns, highlighting relevant symptoms that should prompt presentation to primary care givers.
The need for this is illustrated by studies such as that by Van Nies et al., which found that a signiﬁcant
proportion of individuals at risk of RA with subacute disease courses postponed seeking medical help
as they thought their disease would be self-limiting [44e46]. Public health messaging to address this,
recognising the frequently subacute nature of the onset of RA, may promote rapid help seeking.
Furthermore, the optimisation of the selection of symptoms to include in algorithms to predict the
development of RA in patients with CSA, palindromic rheumatism and UA should improve the per-
formance of such algorithms and consequently the management of these patients.Practice points
1) Many patients who eventually develop RA present with musculoskeletal symptoms in the
absence of joint swelling.
2) Relevant symptoms include those typically associatedwith established RA such as joint pain
and stiffness. Other symptoms include colour changes to the skin around the joints and
transient nodules.
3) Many of these symptoms have been incorporated into algorithms that predict the devel-
opment of RA in patients with RA-related autoantibodies, clinically suspect arthralgia and
undifferentiated arthritis.
Research agenda
1) Further quantitative work should be undertaken in both primary and secondary care,
building on published qualitative data, to identify those symptoms that differentiate patients
with musculoskeletal symptoms who will eventually develop RA from those who will not.Conﬂict of interest
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